1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 THR B 27 - PRO B 28 MODEL 2 OMEGA =213.93 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION THR B 27 - PRO B 28 MODEL 9 OMEGA =213.50 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION Hua, Q.X. Shoelson, S.E. Inouye, K. Weiss, M.A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 90 582 586 10.1073/pnas.90.2.582 8421693 Paradoxical structure and function in a mutant human insulin associated with diabetes mellitus. 1993 US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 89 2379 Structure and Dynamics of Des-Pentapeptide-Insulin in Solution: The Molten-Globule Hypothesis 1992 UK Nature NATUAS 0006 0028-0836 354 238 Receptor Binding Redefined by a Structural Switch in a Mutant Human Insulin 1991 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2383.698 INSULIN 1 man polymer 3373.857 INSULIN F24S 1 man polymer no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A polypeptide(L) no no FVNQHLCGSHLVEALYLVCGERGSFYTPKT FVNQHLCGSHLVEALYLVCGERGSFYTPKT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens human Homo sample 9606 PANCREAS Homo sapiens pdbx_database_status struct_conf struct_conf_type repository Initial release Version format compliance Version format compliance Derived calculations Other 1 0 1994-01-31 1 1 2008-03-24 1 2 2011-07-13 1 3 2017-11-29 _pdbx_database_status.process_site Y BNL 1993-03-05 REL REL 10 HAVEL refinement DGII BRUNGER refinement X-PLOR GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B HIS 10 n 10 HIS 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B SER 24 n 24 SER 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B PRO 28 n 28 PRO 28 B LYS 29 n 29 LYS 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 4 B B HG HG1 SER THR 24 30 1.30 2 B B THR PRO 27 28 -146.07 9 B B THR PRO 27 28 -146.50 1 B ARG 22 0.314 SIDE CHAIN 2 B ARG 22 0.278 SIDE CHAIN 3 B ARG 22 0.308 SIDE CHAIN 4 B ARG 22 0.287 SIDE CHAIN 5 B ARG 22 0.140 SIDE CHAIN 6 B ARG 22 0.198 SIDE CHAIN 7 B ARG 22 0.309 SIDE CHAIN 8 B ARG 22 0.303 SIDE CHAIN 9 B ARG 22 0.136 SIDE CHAIN 10 B ARG 22 0.261 SIDE CHAIN 1 -4.17 0.60 121.00 116.83 A A A CB CG CD2 TYR TYR TYR 19 19 19 N 1 3.86 0.60 121.00 124.86 A A A CB CG CD1 TYR TYR TYR 19 19 19 N 1 8.26 1.10 114.20 122.46 B B B CA CB SG CYS CYS CYS 19 19 19 N 1 -3.53 0.50 120.30 116.77 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 4 -3.70 0.60 121.00 117.30 B B B CB CG CD2 TYR TYR TYR 26 26 26 N 5 -4.28 0.50 120.30 116.02 B B B NE CZ NH2 ARG ARG ARG 22 22 22 N 6 6.96 1.10 114.20 121.16 A A A CA CB SG CYS CYS CYS 20 20 20 N 9 6.74 1.10 114.20 120.94 A A A CA CB SG CYS CYS CYS 11 11 11 N 1 A ILE 2 -27.70 -53.71 1 A GLU 4 -25.92 -52.39 1 A CYS 7 -121.00 -53.51 1 A SER 9 -125.19 -161.84 1 A GLU 17 -25.79 -51.03 1 A CYS 20 -28.09 -60.88 1 B VAL 2 -115.35 59.19 1 B VAL 18 -103.27 -78.93 1 B PHE 25 -113.41 -96.84 1 B THR 27 -118.36 57.99 2 A CYS 6 -86.54 32.48 2 A GLU 17 -28.35 -42.14 2 A CYS 20 -65.67 -176.67 2 B VAL 2 -117.35 70.85 2 B ASN 3 9.64 55.11 2 B LEU 6 -106.66 -81.32 2 B CYS 7 76.92 -70.71 2 B VAL 18 -89.80 -73.43 2 B CYS 19 -126.92 -89.91 2 B SER 24 -19.29 164.89 2 B THR 27 -143.49 -62.11 3 A GLU 4 -21.44 -57.94 3 A CYS 11 -122.25 -168.37 3 A CYS 20 -118.75 -168.34 3 B ASN 3 -102.78 63.89 3 B SER 9 -130.65 -35.46 3 B CYS 19 -106.15 55.80 3 B LYS 29 -147.96 59.92 4 A VAL 3 -79.83 31.27 4 A GLN 5 -108.27 -63.38 4 A GLU 17 -26.32 -42.70 4 A ASN 18 -27.75 -44.39 4 A CYS 20 -35.82 169.23 4 B ASN 3 -105.20 41.32 4 B SER 9 -141.59 -41.51 4 B VAL 18 -103.63 -67.26 4 B GLU 21 104.15 -44.55 4 B ARG 22 19.75 50.87 4 B SER 24 7.62 86.43 4 B PHE 25 5.26 -74.30 4 B THR 27 -6.68 -53.31 4 B PRO 28 -21.52 -59.77 5 A GLU 4 -23.00 -40.73 5 A CYS 7 -122.39 -55.74 5 A THR 8 -109.97 68.32 5 A SER 9 122.66 -175.02 5 A TYR 19 -121.84 -51.02 5 A CYS 20 -16.05 80.55 5 B ASN 3 -119.19 51.60 5 B HIS 10 -26.59 -52.50 5 B CYS 19 -140.66 -70.64 5 B PHE 25 -141.54 40.13 5 B TYR 26 103.57 79.60 5 B PRO 28 -54.41 80.41 5 B LYS 29 -107.92 50.65 6 A VAL 3 -104.74 49.85 6 A SER 9 -128.15 -153.93 6 A CYS 20 -116.47 77.29 6 B VAL 2 -108.03 62.20 6 B ASN 3 -21.89 85.30 6 B CYS 7 109.56 37.62 6 B SER 9 144.26 -9.42 6 B CYS 19 -144.47 -67.49 6 B GLU 21 34.20 58.77 6 B ARG 22 -111.35 59.03 6 B SER 24 15.02 -70.77 6 B PHE 25 -105.32 51.48 6 B PRO 28 -10.45 -67.63 6 B LYS 29 -140.82 37.27 7 A ILE 2 -107.64 -80.07 7 A CYS 6 -65.11 4.98 7 A SER 9 -134.12 -159.38 7 A CYS 20 -115.00 -166.16 7 B ASN 3 -112.86 55.49 7 B CYS 7 -119.47 75.10 7 B CYS 19 -107.06 52.93 7 B GLU 21 -135.94 -50.46 7 B PHE 25 -113.61 59.23 8 A VAL 3 -28.60 -46.08 8 A GLU 4 -26.41 -41.89 8 A GLU 17 -27.02 -42.24 8 A CYS 20 -45.23 156.67 8 B TYR 16 -36.95 -37.64 8 B LYS 29 -116.47 66.85 9 A VAL 3 -96.74 41.09 9 A LEU 13 -28.57 -57.22 9 A GLU 17 -28.85 -38.15 9 A ASN 18 -24.61 -42.01 9 B ASN 3 -110.51 64.57 9 B CYS 7 -130.87 -149.63 9 B VAL 18 -93.39 -69.13 9 B CYS 19 -120.01 -60.09 9 B GLU 21 -95.13 53.57 9 B SER 24 -118.47 78.55 9 B PRO 28 -24.24 -53.35 10 A CYS 6 -92.78 34.92 10 A GLU 17 -33.58 -35.68 10 A ASN 18 -31.78 -38.02 10 A CYS 20 -18.85 -55.97 10 B ASN 3 -115.60 54.92 10 B GLU 21 40.49 82.91 10 B SER 24 5.65 -75.62 10 B THR 27 4.85 82.66 10 B PRO 28 -53.80 103.79 model building X-PLOR refinement X-PLOR phasing X-PLOR INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY SER (F24S) (NMR, REPRESENTATIVE PLUS 9 STRUCTURES) PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS 1 N N 2 N N A ILE 2 A ILE 2 HELX_P A THR 8 A THR 8 1 H1 7 A SER 12 A SER 12 HELX_P A ASN 18 A ASN 18 1 H2 7 B SER 9 B SER 9 HELX_P B CYS 19 B CYS 19 1 H3 11 disulf 2.020 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.020 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.019 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 HORMONE HORMONE INS_HUMAN UNP 1 90 P01308 INS_HUMAN UNP 2 25 P01308 90 110 1HIQ 1 21 P01308 A 1 1 21 25 54 1HIQ 1 30 P01308 B 2 1 30 2 PHE ENGINEERED MUTATION SER 24 1HIQ B P01308 UNP 48 24 1 P 1